Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Next Previous
X
Search
Trial Profile

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Acute coronary syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms dal-GenE-2
  • Sponsors DalCor Pharmaceuticals

    • Most Recent Events

    • 09 Oct 2023 Status changed from not yet recruiting to recruiting.
    • 13 Sep 2023 According to a DalCor Pharmaceuticals media release, The Series D financing includes the participation of Fonds de Developpement Economique from the Quebec government managed by Investissement Quebec and Fonds Propres d' Investissement Quebec as well as current investors including Andes Growth, TB Pharma, Fonds de Solidarite FTQ, and CTI Life Sciences.
    • 13 Sep 2023 According to a DalCor Pharmaceuticals media release, this trial is expected to start in Q3 2023 with an interim efficacy analysis in 2026, and completion anticipated in 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top